In another small study of women under the age of 40 years with stage III–IV melanoma, median AMH levels and antral follicle counts determined by pelvic ultrasound were lower in the group who were treated with CPIs (n=6) vs those who did not (n=6) [50]. The gene discussed is AMH; the disease is melanoma.